KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Long-Term Deferred Tax (2017 - 2019)

Amneal Pharmaceuticals has reported Long-Term Deferred Tax over the past 3 years, most recently at $391.9 million for Q2 2019.

  • For Q2 2019, Long-Term Deferred Tax rose 4.86% year-over-year to $391.9 million; the TTM value through Jun 2019 reached $391.9 million, up 4.86%, while the annual FY2018 figure was $373.2 million, 41454.45% up from the prior year.
  • Long-Term Deferred Tax for Q2 2019 was $391.9 million at Amneal Pharmaceuticals, up from $382.9 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $391.9 million in Q2 2019 and troughed at $898000.0 in Q4 2017.
  • A 3-year average of $314.8 million and a median of $373.4 million in 2018 define the central range for Long-Term Deferred Tax.
  • Biggest five-year swings in Long-Term Deferred Tax: soared 41454.45% in 2018 and later increased 4.86% in 2019.
  • Year by year, Long-Term Deferred Tax stood at $898000.0 in 2017, then soared by 41454.45% to $373.2 million in 2018, then rose by 5.02% to $391.9 million in 2019.
  • Business Quant data shows Long-Term Deferred Tax for AMRX at $391.9 million in Q2 2019, $382.9 million in Q1 2019, and $373.2 million in Q4 2018.